EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieMultizentrische Studie

ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis

Christophe Milesi iD, Erika Nogue, Julien Baleine, Lionel Moulis, Robin Pouyau, Arthur Gavotto, David Brossier, Guillaume Mortamet, Gilles Cambonie, GFRUP Respiratory Study Group

Pediatric Pulmonology · 2024-04 · 59 (4) · 982-990

DOI: 10.1002/ppul.26860 ↗

At a glance

Randomisierte kontrollierte Studie in Pediatric Pulmonology, published online on 2024-01-10. Written by Christophe Milesi and 9 co-authors. Institution: Pediatric Intensive Care Unit, Arnaud de Villeneuve University Hospital, Montpellier, France. Major MEDLINE topics: Bronchiolitis, Viral, Bronchiolitis, Pneumonia, Respiratory Distress Syndrome. Cited 7 times so far (Crossref); 26 references. Funded by: None.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

High‐flow nasal cannula (HFNC) is commonly used as first step respiratory support in infants with moderate‐to‐severe acute viral bronchiolitis (AVB). This device, however, fails to effectively manage respiratory distress in about a third of patients, and data are limited on determinants of patient response. The respiratory rate–oxygenation (ROX) index is a relevant tool to predict the risk for HFNC failure in adult patients with lower respiratory tract infections. The primary objective of this study was to assess the relationship between ROX indexes collected before and 1 h after HFNC initiation, and HFNC failure occurring in the following 48 h in infants with AVB.

Method

This is an ancillary study to the multicenter randomized controlled trial TRAMONTANE 2, that included 286 infants of less than 6 months with moderate‐to‐severe AVB. Collection of physiological variables at baseline (H0), and 1 h after HFNC (H1), included heart rate (HR), respiratory rate (RR), fraction of inspired oxygen (FiO 2 ), respiratory distress score (modified Wood's Clinical Asthma Score [mWCAS]), and pain and discomfort scale (EDIN). ROX and ROX‐HR were calculated as and , respectively. Predefined HFNC failure criteria included increase in respiratory distress score or RR, increase in discomfort, and severe apnea episodes. The accuracies of ROX, ROX‐HR indexes and clinical variable to predict HFNC failure were assessed using receiver operating curve analysis. We analyzed predictive factors of HFNC failure using multivariate logistic regressions.

Result

HFNC failure occurred in 111 of 286 (39%) infants, and for 56 (50% of the failure) of them within the first 6 h. The area under the curve of ROX indexes at H0 and H1 were, respectively, 0.56 (95% confidence interval [CI] 0.48–0.63, p = 0.14), 0.56 (95% CI 0.49–0.64, p = 0.09). ROX‐HR performances were better but remained poorly discriminant. HFNC failure was associated with higher mWCAS score at H1 ( p < 0.01) and lower decrease in EDIN scale during the first hour of HFNC delivery ( p = 0.02). In the multivariate analyses, age and mWCAS score were were found to be independent factors associated with HFNC failure at H0. At H1, weight and mWCAS were associated factors.

Conclusion

In this study, neither ROX index, nor physiological variables usually collected in infants with AVB had early discriminatory capacity to predict HFNC failure.

Subjects

MeSH terms (MEDLINE)

Bronchiolitis, ViralBronchiolitisPneumoniaRespiratory Distress SyndromeRespiratory InsufficiencyInfantAdultHumansCannulaRespiratory RateOxygen Inhalation TherapyDyspnea

Author keywords

bronchiolitisfailurehigh‐flow nasal cannulainfantrisk prediction

Authors and institutions

  • Pediatric Intensive Care Unit, Arnaud de Villeneuve University Hospital, Montpellier, France.
  • Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France.
  • Pediatric Intensive Care Unit, Woman-Mother-Child University Hospital, Lyon, France.
  • Pediatric Intensive Care Unit, University Hospital Caen-Normandy, France.
  • Pediatric Intensive Care Unit, Grenoble University Hospital, La Tronche, France.

ORCID profiles: Christophe Milesi

Funding

  • None

Cite

APA

Milesi, C., Nogue, E., Baleine, J., Moulis, L., Pouyau, R., Gavotto, A., Brossier, D., Mortamet, G., Cambonie, G., & GFRUP Respiratory Study Group (2024). ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis. Pediatric Pulmonology, 59(4), 982-990. https://doi.org/10.1002/ppul.26860

Vancouver

Milesi C, Nogue E, Baleine J, Moulis L, Pouyau R, Gavotto A, et al. ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis. Pediatric Pulmonology. 2024;59(4):982-990. doi:10.1002/ppul.26860

BibTeX
@article{Milesi2024,
  author = {Milesi, Christophe and Nogue, Erika and Baleine, Julien and Moulis, Lionel and Pouyau, Robin and Gavotto, Arthur and Brossier, David and Mortamet, Guillaume and Cambonie, Gilles and GFRUP Respiratory Study Group, GFRUP Respiratory Study Group},
  title = {ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis},
  journal = {Pediatric Pulmonology},
  year = {2024},
  volume = {59},
  number = {4},
  pages = {982--990},
  doi = {10.1002/ppul.26860}
}
Start for free →